Literature DB >> 19647448

The Janus faces of CD40 in cancer.

Angelica S I Loskog1, Aristides G Eliopoulos.   

Abstract

CD40 is a TNF receptor family member that is widely recognized for its prominent role in immune regulation and homeostasis. Expression of CD40 is not restricted to normal lymphoid cells but is also evident in the majority of haemopoietic and epithelial malignancies where it has been implicated in oncogenic events. Accumulating evidence, however, suggests that the CD40 pathway can be exploited for cancer therapy by virtue of its ability to stimulate the host anti-tumor immune response, normalize the tumor microenvironment and directly suppress the growth of CD40-positive tumors. Here, we provide an overview of the multifaceted functions of the CD40 pathway in cancer and its emerging role in the treatment of malignancy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647448     DOI: 10.1016/j.smim.2009.07.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  26 in total

1.  Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Chengwen Liu; Carol M Lewis; Yanyan Lou; Chunyu Xu; Weiyi Peng; Yan Yang; Alexander H Gelbard; Gregory Lizée; Dapeng Zhou; Willem W Overwijk; Patrick Hwu
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

2.  TRAF2 Ser-11 Phosphorylation Promotes Cytosolic Translocation of the CD40 Complex To Regulate Downstream Signaling Pathways.

Authors:  Lauren M Workman; Laiqun Zhang; Yumei Fan; Weizhou Zhang; Hasem Habelhah
Journal:  Mol Cell Biol       Date:  2020-04-13       Impact factor: 4.272

3.  MicroRNAs in pancreatic ductal adenocarcinoma.

Authors:  Jong Y Park; James Helm; Domenico Coppola; Donghwa Kim; Mokenge Malafa; Seung Joon Kim
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

4.  CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.

Authors:  L Liljenfeldt; L C Dieterich; A Dimberg; S M Mangsbo; A S I Loskog
Journal:  Cancer Gene Ther       Date:  2014-01-31       Impact factor: 5.987

5.  RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.

Authors:  Laiqun Zhang; Ken Blackwell; Lauren M Workman; Songhai Chen; Marshall R Pope; Siegfried Janz; Hasem Habelhah
Journal:  Mol Cell Biol       Date:  2015-07-20       Impact factor: 4.272

6.  Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Authors:  Yin Liu; Hong-Wei Wu; Michael A Sheard; Richard Sposto; Srinivas S Somanchi; Laurence J N Cooper; Dean A Lee; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2013-02-01       Impact factor: 12.531

7.  The aryl hydrocarbon receptor repressor - More than a simple feedback inhibitor of AhR signaling: Clues for its role in inflammation and cancer.

Authors:  Christoph F A Vogel; Thomas Haarmann-Stemmann
Journal:  Curr Opin Toxicol       Date:  2017-03-01

8.  NSCLC and the alternative pathway of NF-κB: uncovering an unknown relation.

Authors:  Fotinos-Ioannis D Dimitrakopoulos; Anna G Antonacopoulou; Anastasia Kottorou; Helen Vlotinou; Nikolaos D Panagopoulos; Dimitrios Dougenis; Chrisoula Scopa; Helen Papadaki; Haralabos P Kalofonos
Journal:  Virchows Arch       Date:  2012-05-05       Impact factor: 4.064

9.  CD40 -1C>T polymorphism and the risk of lung cancer in a Chinese population.

Authors:  Gang Zhou; Ying Wang; Ziyao Fang; Rongrong Liu; Anhui Wang; Feng Zhao; Lihua Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Association of CD40 gene polymorphisms with sporadic breast cancer in Chinese Han women of Northeast China.

Authors:  Chen Shuang; Li Dalin; Yuan Weiguang; Fu Zhenkun; Xu Fengyan; Pang Da; Dianjun Li
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.